Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,260 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,163
Recruiting: 2,261
Ph III recruiting: 270
Growth YoY: +12.5%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,895)

clinicaltrialsPublishedShowing 951–1,000 of 1,264 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06211036	Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab(DeLLphi-305)	active not recruiting	Phase 3	563	AmgenINDUSTRY	29	Dec 17, 2025	clinicaltrials
NCT06682572	A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J)	active not recruiting	Phase 2	16	Verastem, Inc.INDUSTRY